Drug Trial Radar · NCT02694523
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Jul 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
684
Actual
Start
Mar 2016
Primary completion
Aug 2017
Study completion Aug 2017
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- Collaborators
- Boehringer Ingelheim
- First posted
- Feb 29, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized double blind, double dummy, active comparator controlled, parallel design study that is performed to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) compared to adalimumab to support registration for the treatment of moderate to severe chronic plaque psoriasis in adult patients.
Conditions
- Psoriasis
Interventions
risankizumabDrug
Risankizumab administered by subcutaneous (SC) injection
adalimumabBiological
Adalimumab pre-filled syringe, administered by subcutaneous (SC) injection
placebo for risankizumabDrug
Placebo risankizumab administered by subcutaneous (SC) injection
placebo for adalimumabBiological
Placebo for adalimumab pre-filled syringe, administered by subcutaneous (SC) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A)Time frame: Week 16
- Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 (Part A)Time frame: Week 16
- Percentage of Participants Who Were Re-Randomized to Receive Either Adalimumab or Risankizumab in Part B Achieving PASI90 at Week 44 (Part B)Time frame: Week 44
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.